Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Matinas BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$6.67M. For fiscal 2025 it was -$6.96M. The highest annual figure on record is -$3.71M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.96M | – |
| FY2024 | Dec 31, 2024 | -$24.59M | – |
| FY2023 | Dec 31, 2023 | -$23.77M | – |
| FY2022 | Dec 31, 2022 | -$24.59M | – |
| FY2021 | Dec 31, 2021 | -$24.74M | – |
| FY2020 | Dec 31, 2020 | -$24.21M | – |
| FY2019 | Dec 31, 2019 | -$18.92M | – |
| FY2018 | Dec 31, 2018 | -$14.65M | – |
| FY2017 | Dec 31, 2017 | -$16.50M | – |
| FY2016 | Dec 31, 2016 | -$8.26M | – |
| FY2015 | Dec 31, 2015 | -$9.91M | – |
| FY2014 | Dec 31, 2014 | -$10.46M | – |
| FY2013 | Dec 31, 2013 | -$3.71M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.72M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.35M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.56M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.12M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.63M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.98M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.56M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.84M | – |
See a number that looks wrong?